Salient

XMAn Update - A Database of Homo sapiens Mutated Peptides

Haueis, J. R. S., Lazar, I. M.
10.64898/2026.08.24.746771 · was preprinted
biomedical
Surfaced because: matches the platform's topic region.
relevance 0.34 openness 0.00 novelty 0.36

Abstract

Mass spectrometry (MS) is the leading technology for identifying proteins in complex biological samples. It relies on the use of tandem MS alongside a reference database of canonical protein sequences to computationally identify peptides and their parent proteins. The canonical sequences represent the most widely expressed and functionally validated forms of proteins. Consequently, disease-induced or disease-supportive variants, such as those associated with cancer, will evade detection if they are absent from the database. To address this challenge, this study introduces a revised release of the Unkown Mutation Analysis (XMAn) database by incorporating coding missense and nonsense mutations from the latest versions (v103) of the COSMIC Genome Screen Mutants (GSM) and Cancer Gene Census (CGC) datasets in two distinct FASTA-formatted peptide databases comprising 3,848,499 and 312,658 variants, respectively. The mutated peptides were matched to reviewed, non-redundant UniProt Homo sapiens protein entries (18,362 and 746), and characterized in terms of nucleotide- and amino acid mutation frequencies, peptide length distributions, and associations between specific single-nucleotide (SNV) and single amino acid (SAAVs) variants. Applied to the analysis of MDA-MB-231 breast cancer cell-membrane protein fractions, the database enabled the identification of 300+ high-quality variant peptides - several localized to functional protein-binding and catalytic domains - and 23 aberrant protein products mapped to the CGC dataset. The database is hosted and available for download on Zenodo (XMAn/gsm doi: 10.5281/zenodo.21781023; XMAn/cgc doi: 10.5281/zenodo.21781514) or can be accessed through https://sites.google.com/vt.edu/xman-db/home.

Lifecycle

Discussion

No qualifying discussion yet.